Zentalis Pharmaceuticals (ZNTL) Common Equity (2019 - 2026)

Zentalis Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $182.7 million for Q1 2026.

• In Q1 2026, Common Equity fell 38.15% year-over-year to $182.7 million; the TTM figure through Mar 2026 stood at $182.7 million (down 38.15% YoY), while the FY2025 annual figure was $216.2 million, down 35.88% from the prior year.
• Common Equity for Q1 2026 stood at $182.7 million, down from $216.2 million in the prior quarter.
• The five-year high for Common Equity was $523.3 million in Q2 2023, with the low at $182.7 million in Q1 2026.
• The 5-year median for Common Equity is $382.6 million (2024), against an average of $366.7 million.
• The sharpest annual moves came in 2022 and 2026: Common Equity surged 90.96% in 2022, then tumbled 38.15% in 2026.
• Zentalis Pharmaceuticals' Common Equity stood at $434.0 million in 2022, then gained by 0.78% to $437.4 million in 2023, then slipped by 22.91% to $337.2 million in 2024, then slumped by 35.88% to $216.2 million in 2025, then decreased by 15.51% to $182.7 million in 2026.
• Business Quant data shows ZNTL's Common Equity at $182.7 million in Q1 2026, $216.2 million in Q4 2025, and $252.9 million in Q3 2025.